Biologics are a fundamental therapeutic resource for patients with moderate to severe chronic plaque psoriasis because they well conjugate effectiveness and safety. Several classes of biologics are available, including TNF-α inhibitors (infliximab, etanercept, adalimumab and certolizumab pegol), IL-12/23 inhibitor (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab and brodalumab) and IL-23 inhibitors (guselkumab, risankizumab and tildrakizumab). Each class of biologics has distinct characteristics.
Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasis
Piaserico, S;
2020
Abstract
Biologics are a fundamental therapeutic resource for patients with moderate to severe chronic plaque psoriasis because they well conjugate effectiveness and safety. Several classes of biologics are available, including TNF-α inhibitors (infliximab, etanercept, adalimumab and certolizumab pegol), IL-12/23 inhibitor (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab and brodalumab) and IL-23 inhibitors (guselkumab, risankizumab and tildrakizumab). Each class of biologics has distinct characteristics.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
